{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:31:43Z","timestamp":1790883103584,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008130","name":"Helsinn Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s40257-021-00591-x","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T11:03:54Z","timestamp":1614769434000},"page":"407-414","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["The PROVe Study: US Real-World Experience with Chlormethine\/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9099-7614","authenticated-orcid":false,"given":"Ellen J.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Guitart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Querfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Girardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Musiek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg E.","family":"Akilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Angello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa J.","family":"Geskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,3]]},"reference":[{"issue":"10","key":"591_CR1","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","volume":"105","author":"R Willemze","year":"2005","unstructured":"Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768\u201385.","journal-title":"Blood"},{"issue":"10","key":"591_CR2","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/ajh.24876","volume":"92","author":"RA Wilcox","year":"2017","unstructured":"Wilcox RA. Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2017;92(10):1085\u2013102.","journal-title":"Am J Hematol."},{"key":"591_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","volume":"77","author":"F Trautinger","year":"2017","unstructured":"Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, et al. European Organisation for research and treatment of cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome - update 2017. Eur J Cancer. 2017;77:57\u201374.","journal-title":"Eur J Cancer."},{"key":"591_CR4","doi-asserted-by":"crossref","unstructured":"Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M, ESMO Guidelines Committee. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(suppl 4):iv30\u201340.","DOI":"10.1093\/annonc\/mdy133"},{"key":"591_CR5","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Primary cutaneous lymphomas. Version 1.2020. 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/default_nojava.aspx. Accessed 25 Jun 2020."},{"key":"591_CR6","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2147\/CMAR.S138661","volume":"11","author":"D Denis","year":"2019","unstructured":"Denis D, Beneton N, Laribi K, Maillard H. Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel. Cancer Manag Res. 2019;11:2241\u201351.","journal-title":"Cancer Manag Res."},{"issue":"3","key":"591_CR7","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S0190-9622(89)70051-7","volume":"20","author":"EC Vonderheid","year":"1989","unstructured":"Vonderheid EC, Tan ET, Kantor AF, Shrager L, Micaily B, Van Scott EJ. Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J Am Acad Dermatol. 1989;20(3):416\u201328.","journal-title":"J Am Acad Dermatol."},{"issue":"5","key":"591_CR8","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S0889-8588(18)30057-1","volume":"9","author":"DL Ramsay","year":"1995","unstructured":"Ramsay DL, Meller JA, Zackheim HS. Topical treatment of early cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995;9(5):1031\u201356.","journal-title":"Hematol Oncol Clin North Am."},{"issue":"2","key":"591_CR9","first-page":"165","volume":"139","author":"YH Kim","year":"2003","unstructured":"Kim YH, Martinez G, Varghese A, Hoppe RT. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol. 2003;139(2):165\u201373.","journal-title":"Arch Dermatol."},{"key":"591_CR10","unstructured":"Valchlor [prescribing information]. Iselin, NJ: Helsinn Therapeutics (US) Inc. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/202317s009lbl.pdf. Accessed 25 Jun 2020."},{"key":"591_CR11","doi-asserted-by":"crossref","unstructured":"Lessin SR, Duvic M, Guitart J, Pandya AG, Strober BE, Olsen EA, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013;149(1):25\u201332.","DOI":"10.1001\/2013.jamadermatol.541"},{"key":"591_CR12","doi-asserted-by":"crossref","unstructured":"Kim YH, Duvic M, Guitart J, Lessin S. Efficacy and safety of mechlorethamine (MCH) 0.04% gel in mycosis fungoides (MF) after treatment with topical MCH 0.02%. J Clin Oncol. 2014;32(suppl 15): abstract 9093.","DOI":"10.1200\/jco.2014.32.15_suppl.9093"},{"key":"591_CR13","unstructured":"Ledaga [summary of product characteristics]. Dublin, Ireland: Helsinn Birex Pharmaceuticals Ltd. 2017. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ledaga-epar-product-information_en.pdf. Accessed 25 Jun 2020."},{"key":"591_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.12.009","author":"C Querfeld","year":"2021","unstructured":"Querfeld C, Geskin LJ, Kim EJ, Scarisbrick JJ, Quaglino P, Papadavid E, Angello JT, Ortiz-Romero PL. Lack of Systemic Absorption of Topical Mechlorethamine Gel in Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma. J Invest Dermatol. 2021. https:\/\/doi.org\/10.1016\/j.jid.2020.12.009","journal-title":"J Invest Dermatol"},{"issue":"3","key":"591_CR15","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.jaad.2019.12.070","volume":"83","author":"EJ Kim","year":"2020","unstructured":"Kim EJ, Geskin L, Guitart J, Querfeld C, Girardi M, Musiek A, et al. Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: preliminary findings from a prospective observational study. J Am Acad Dermatol. 2020;83(3):928\u201330.","journal-title":"J Am Acad Dermatol."},{"issue":"11","key":"591_CR16","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/archderm.1997.03890470111018","volume":"133","author":"MM Chren","year":"1997","unstructured":"Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133(11):1433\u201340.","journal-title":"Arch Dermatol."},{"issue":"9","key":"591_CR17","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/jid.2011.138","volume":"131","author":"CA Prinsen","year":"2011","unstructured":"Prinsen CA, Lindeboom R, de Korte J. Interpretation of Skindex-29 scores: cutoffs for mild, moderate, and severe impairment of health-related quality of life. J Invest Dermatol. 2011;131(9):1945\u20137.","journal-title":"J Invest Dermatol."}],"updated-by":[{"DOI":"10.1007\/s40257-022-00676-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000}}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00591-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-021-00591-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00591-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T07:05:10Z","timestamp":1647414310000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-021-00591-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,3]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["591"],"URL":"https:\/\/doi.org\/10.1007\/s40257-021-00591-x","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40257-022-00676-1","asserted-by":"object"}]},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,3]]},"assertion":[{"value":"23 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40257-022-00676-1","URL":"https:\/\/doi.org\/10.1007\/s40257-022-00676-1","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by Helsinn Healthcare SA, who were involved in the analysis plan and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, and approval of the manuscript and the decision to submit it for publication. Writing and editorial assistance was funded by Helsinn Healthcare SA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"E.J. Kim has received research support from and\/or acted as principal investigator for Actelion, Galderma, MedImmune, and Soligenix; has received consultant, speaking, or travel support from Actelion, Galderma, Helsinn, and Soligenix; and has served on a scientific advisory board for Helsinn and Kyowa Kirin. J. Guitart has received research support from Galderma and Soligenix and served on a scientific advisory board for Helsinn, Kyowa Kirin, miRagen, and Leo Pharma. C. Querfeld has received a research grant from Celgene; acted as clinical investigator for Celgene, Trillium, miRagen, Bioniz, and Kyowa Kirin; and served on a steering committee or advisory board for Helsinn\/Actelion, miRagen, Bioniz, Trillium, and Kyowa Kirin. M. Girardi has served on an advisory board for Helsinn and Mallinckrodt and received research support and\/or acted as principal investigator for AbbVie and Soligenix. A. Musiek has acted as investigator for Elorac, Soligenix, miRagen, Pfizer, Menlo, and Connect and served on an advisory board for Kyowa and Helsinn. O.E. Akilov has received research support from Trillium Therapeutics, Kyowa Kirin, and Pfizer; served as a clinical investigator for Celgene, Trillium Therapeutics, Bioniz, Kyowa, Soligenix, Galderma, and Innate Pharma; and received consulting fees or honorarium from Kyowa Kirin, Bioniz, and Dr. Reddy\u2019s. J.T. Angello and W.L. Bailey are employed by Helsinn Therapeutics (U.S.), Inc. L.J. Geskin has received a research grant from Actelion; consulting fees or honorarium from Actelion, Helsinn, Mallinckrodt, Sanofi, and Regeneron; and served on a speakers\u2019 bureau for Helsinn.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in compliance with the Declaration of Helsinki and the International Conference on Harmonization guidelines. The appropriateness of the study protocol and all risks and benefits to participants were approved by institutional review boards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Prof. EJK and JTA had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: EJK, JG, CQ, MG, AM, OEA, JTA, WLB, LJG. Analysis and interpretation of the data: EJK, JG, CQ, MG, AM, JTA, WLB, LJG. Drafting of the article: EJK, JG, CQ, MG, AM, OEA, JTA, WLB, LJG. Critical revision of the article for important intellectual content: EJK, JG, CQ, MG, AM, OEA, JTA, WLB, LJG.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}